Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Neurofilament light chain
pediatric MS
teriflunomide
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
pubmed:
13
1
2023
medline:
3
3
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS). Evaluate plasma neurofilament light chain (pNfL) concentrations in TERIKIDS. Patients received placebo or teriflunomide (14 mg adult equivalent) for up to 96 weeks in the double-blind (DB) period. In the open-label extension (OLE), all patients received teriflunomide until up to 192 weeks after randomization. pNfL was measured using single-molecule array assay (Simoa Baseline mean age was 14.5 years; 69.4% were female. Baseline geometric least square mean pNfL levels were similar for teriflunomide ( Teriflunomide treatment was associated with significantly reduced pNfL levels in children with RMS. NCT02201108.
Sections du résumé
BACKGROUND
The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS).
OBJECTIVE
Evaluate plasma neurofilament light chain (pNfL) concentrations in TERIKIDS.
METHODS
Patients received placebo or teriflunomide (14 mg adult equivalent) for up to 96 weeks in the double-blind (DB) period. In the open-label extension (OLE), all patients received teriflunomide until up to 192 weeks after randomization. pNfL was measured using single-molecule array assay (Simoa
RESULTS
Baseline mean age was 14.5 years; 69.4% were female. Baseline geometric least square mean pNfL levels were similar for teriflunomide (
CONCLUSION
Teriflunomide treatment was associated with significantly reduced pNfL levels in children with RMS.
CLINICALTRIALS.GOV IDENTIFIER
NCT02201108.
Identifiants
pubmed: 36632983
doi: 10.1177/13524585221144742
pmc: PMC9972233
doi:
Substances chimiques
teriflunomide
1C058IKG3B
Crotonates
0
Toluidines
0
Banques de données
ClinicalTrials.gov
['NCT02201108']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-394Commentaires et corrections
Type : CommentIn
Références
Ann Clin Transl Neurol. 2020 Jun;7(6):945-955
pubmed: 32452160
Neurology. 2007 Apr 17;68(16 Suppl 2):S37-45
pubmed: 17438237
Mult Scler. 2022 Sep;28(10):1553-1561
pubmed: 35282740
Drugs. 2014 Apr;74(6):659-74
pubmed: 24740824
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
Ann Neurol. 2020 Jul;88(1):42-55
pubmed: 32267005
BMC Neurol. 2015 Sep 25;15:174
pubmed: 26407848
Neurology. 2016 Aug 30;87(9 Suppl 2):S74-81
pubmed: 27572865
Lancet Neurol. 2022 Mar;21(3):246-257
pubmed: 35182510
Lancet Neurol. 2021 Dec;20(12):1001-1011
pubmed: 34800398
N Engl J Med. 2007 Jun 21;356(25):2603-13
pubmed: 17582070
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422
pubmed: 29209636
Mult Scler. 2022 Apr;28(4):573-582
pubmed: 34378446
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Int J Mol Sci. 2022 May 24;23(11):
pubmed: 35682558
J Neuroinflammation. 2018 Jul 18;15(1):209
pubmed: 30021640
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
Neurol Neuroimmunol Neuroinflamm. 2020 May 13;7(4):
pubmed: 32404429
J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1324-1330
pubmed: 31611264
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753